American Association for Cancer Research Apr 18 2025 Bottom line: A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to immune-related adverse events (irAEs) continued to experience long-term disease control. Journal in which the study was published: Clinical Cancer Research , a journal of the American Association for Cancer Research (AACR) Authors: Senior author Mark Awad, MD, PhD, chief of the Thoracic Oncology Service